Global Sepsis Therapeutics Market Analysis, Trends, and Forecasts, 2018-2024: GIAPREZA – The Only FDA Approved Branded Drug for Sepsis Treatment

Dublin, Feb. 07, 2019 (GLOBE NEWSWIRE) -- The "Sepsis Therapeutics - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

The report provides separate comprehensive analytics for the US, and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2024. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Sepsis Therapeutics in US$ Million.

The report profiles 24 companies including many key and niche players such as:

  • Adrenomed AG (Germany)
  • AM-Pharma B.V. (Netherlands)
  • AMOMED Pharma GmbH (Austria)
  • Asahi Kasei Pharma America (USA)
  • Endacea, Inc. (USA)
  • InflaRx N.V. (Germany)
  • La Jolla Pharmaceutical Company (USA)
  • TaiRx, Inc. (USA)

Key Topics Covered:

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

2. INDUSTRY OVERVIEW
Sepsis - A Prelude
New Treatment Protocols and New Definitions - Every Minute Counts!!
Aging Population: A Key Growth Driver for Sepsis Therapeutics
Antibiotics and Vasopressors - The Current Standard of Care
Current Categories of Antibacterial Agents for First-line Sepsis Treatment
Current Anti-bacterial Drugs used in Sepsis
Current Antifungals used for Sepsis
Current Antivirals used for Sepsis
GIAPREZA - The Only FDA Approved Branded Drug for Sepsis Treatment
Argipressin Gains Approval for Septic Shock in 26 EU countries
Current & Future Analysis
Growth Drivers in a Nutshell
Market Restraints

3. MARKET DYNAMICS
A Market Characterized by High Unmet Medical Needs
Research Activity Enables Increased Awareness of Disease Pathogenesis
Select Sepsis Therapeutics under Phase IV Clinical Trials: As of 2018
Select Sepsis Therapeutics under Phase III Clinical Trials: 2018
Novel Immune-Specific Modes of Action under Focus
Emphasizing on Endothelial Cell Function
HMGB1- A Potential Target for Future Therapies
Nanoparticle Systems Demonstrate Potential for Use in Septic Shock Management
Researchers Employ IL-7 to Increase CD4 and CD8 Immune Cells in Patients
Hydrocortisone Displays Potential in Septic Shock Treatment
Reduced Levels of Vitamin C Characterize Sepsis Patients
Treatment with Hydrocortisone and Vitamin C Demonstrates Positive Impact on Mortality Rate
Intravenous Vitamins + Hydrocortisone Therapy Causes Waves in the Market
Researchers Develop ss-Sepsis-3 Protocol for Evaluation of Sepsis in Animal Models
World Sepsis Day Aims to Result in Improvement in Sepsis Management
NSAIDs Demonstrate Potential to Treat Sepsis

4. SEPSIS: AN OVERVIEW
Sepsis - A Major Life-Threatening Condition
Risk Profile
Most Vulnerable Groups: Newborns and the Elderly
A Growing Threat in Hospital Environment
Types of Sepsis
SIRS
Uncomplicated Sepsis
Severe Sepsis
Septic Shock
Septicemia
Bacteremia
Mortality Rates
Mortality Rate on a Decline
Hospital Re-Admission Rate Remains High
Symptoms to Identify Sepsis Patients
General Symptoms in Sepsis Patients
Symptoms Specific to Source of Infection
Biological Changes in Sepsis Patients
Organ Dysfunction Symptoms in Acute Cases
Common Sources of Sepsis
Stages of Sepsis' Progression
Treatment of Sepsis
General Approaches for Treatment of Severe Sepsis and Septic Shock
Overview of Traditional Treatment Approaches
Anti-microbials
Drug Resistance: The Major Threat to Sepsis Standby Antibiotics
Vasopressors
Corticosteroids
Immunoglobulins
Anticoagulants
Neonatal Sepsis

5. COMPETITIVE LANDSCAPE

5.1 Focus on Select Global Players

5.2 Product Introductions/Approvals
Asahi Kasei Pharma Obtains Phase III Clinical Study Results for ART-123
Argipressin Receives Approval in 26 EU Countries
La Jolla Pharmaceutical Receives FDA Approval for Giapreza Injection
Sepsis Alliance Partners with La Jolla Pharmaceutical

6. GLOBAL MARKET PERSPECTIVE

7. REGIONAL MARKET PERSPECTIVE

7.1 The United States
A. Market Analysis
United States: The Largest Market for Sepsis Therapeutics
Alarming Incidence of Sepsis & Lack of Therapies
Aging Population: A Key Growth Factor

7.2 Rest of World
A. Market Analysis
Aging Population: Key Opportunity Indicator
India
India: High Incidence of Neonatal Sepsis
Key Opportunity Indicator: Aging Population Statistics in Rest of World

8. COMPANY PROFILES

Total Companies Profiled: 24 The United States (7)

  • Canada (3)
  • Japan (1)
  • Europe (8)
    • France (1)
    • Germany (4)
    • Rest of Europe (3)
  • Asia-Pacific (Excluding Japan) (4)
  • Middle East (1)

For more information about this report visit https://www.researchandmarkets.com/research/mwxhwc/global_sepsis?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: 
CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs

Ads